Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for HBV-related severe acute hepatitis (pilot)
jRCTs061180029Completed
- Start
- Aug 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Open-label trial of abatacept in Acute hepatitis B and hepatitis B (HBV) (2 arms). Primary endpoints: Improvement in severe hepatitis at 1 week (PT ≥ 70%), Time to ALT normalization and 1 more. Started Aug 2018; status: completed.
02
Drugs
abatacept
03
Conditions
Acute hepatitis Bhepatitis B (HBV)
Beyond the preview
Go deeper on jRCTs061180029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180029.